Christopher DeSouza
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endothelium, Vascular | 44 | 2023 | 845 | 9.030 |
Why?
| Cell-Derived Microparticles | 13 | 2023 | 58 | 7.440 |
Why?
| Vasodilation | 28 | 2023 | 412 | 6.310 |
Why?
| Endothelin-1 | 16 | 2023 | 167 | 5.720 |
Why?
| Vasoconstriction | 13 | 2023 | 185 | 4.080 |
Why?
| Endothelial Cells | 15 | 2023 | 695 | 3.820 |
Why?
| Fibrinolysis | 15 | 2023 | 160 | 3.400 |
Why?
| Hypertension | 13 | 2023 | 1064 | 2.980 |
Why?
| Nitric Oxide | 13 | 2023 | 832 | 2.820 |
Why?
| Sleep Deprivation | 6 | 2021 | 166 | 2.800 |
Why?
| Forearm | 17 | 2021 | 114 | 2.750 |
Why?
| Tissue Plasminogen Activator | 16 | 2023 | 228 | 2.680 |
Why?
| Vasodilator Agents | 20 | 2023 | 308 | 2.640 |
Why?
| Obesity | 19 | 2023 | 2517 | 2.450 |
Why?
| Overweight | 9 | 2018 | 469 | 2.400 |
Why?
| Aging | 36 | 2011 | 1631 | 2.220 |
Why?
| MicroRNAs | 6 | 2023 | 607 | 2.200 |
Why?
| Spinal Cord Injuries | 4 | 2023 | 173 | 2.140 |
Why?
| Human Umbilical Vein Endothelial Cells | 6 | 2023 | 90 | 2.120 |
Why?
| Exercise | 31 | 2023 | 1609 | 2.090 |
Why?
| Middle Aged | 106 | 2024 | 26999 | 1.880 |
Why?
| Prehypertension | 5 | 2015 | 24 | 1.810 |
Why?
| Cardiovascular Diseases | 11 | 2021 | 1724 | 1.760 |
Why?
| Acetylcholine | 16 | 2023 | 180 | 1.670 |
Why?
| Sleep | 5 | 2021 | 625 | 1.650 |
Why?
| Regional Blood Flow | 23 | 2023 | 414 | 1.630 |
Why?
| HIV Envelope Protein gp120 | 3 | 2019 | 56 | 1.620 |
Why?
| Blood Pressure | 19 | 2021 | 1537 | 1.610 |
Why?
| Apoptosis | 14 | 2023 | 2377 | 1.520 |
Why?
| Polycythemia | 2 | 2021 | 23 | 1.510 |
Why?
| Stem Cells | 8 | 2012 | 546 | 1.490 |
Why?
| Male | 89 | 2024 | 55949 | 1.300 |
Why?
| Nitric Oxide Synthase Type III | 7 | 2023 | 185 | 1.290 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 20 | 1.270 |
Why?
| Nitroprusside | 15 | 2021 | 64 | 1.260 |
Why?
| C-Reactive Protein | 7 | 2015 | 364 | 1.250 |
Why?
| Circulating MicroRNA | 2 | 2019 | 24 | 1.240 |
Why?
| Metabolic Syndrome | 4 | 2016 | 324 | 1.240 |
Why?
| Postmenopause | 17 | 2023 | 300 | 1.190 |
Why?
| Atherosclerosis | 2 | 2023 | 341 | 1.170 |
Why?
| Cell Movement | 8 | 2014 | 867 | 1.160 |
Why?
| Nebivolol | 2 | 2017 | 9 | 1.140 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 57 | 1.080 |
Why?
| Humans | 127 | 2024 | 115587 | 1.070 |
Why?
| Peptides, Cyclic | 7 | 2013 | 262 | 1.070 |
Why?
| Caspase 3 | 5 | 2017 | 237 | 1.070 |
Why?
| Adult | 64 | 2023 | 30718 | 1.030 |
Why?
| Vasoconstrictor Agents | 6 | 2023 | 113 | 0.970 |
Why?
| Female | 78 | 2023 | 59913 | 0.960 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 81 | 0.910 |
Why?
| Aged | 60 | 2021 | 19251 | 0.880 |
Why?
| Dietary Fats | 2 | 2015 | 289 | 0.840 |
Why?
| Inflammation Mediators | 4 | 2021 | 479 | 0.830 |
Why?
| Blood Coagulation | 2 | 2021 | 221 | 0.800 |
Why?
| Estrogen Replacement Therapy | 9 | 2003 | 116 | 0.760 |
Why?
| Altitude | 3 | 2021 | 409 | 0.760 |
Why?
| Vasomotor System | 1 | 2021 | 38 | 0.740 |
Why?
| Vascular Diseases | 1 | 2023 | 230 | 0.740 |
Why?
| Case-Control Studies | 11 | 2021 | 3022 | 0.710 |
Why?
| Oxidative Stress | 7 | 2021 | 1093 | 0.700 |
Why?
| Cross-Sectional Studies | 22 | 2023 | 4435 | 0.700 |
Why?
| Hemodynamics | 8 | 2021 | 968 | 0.690 |
Why?
| Physical Endurance | 15 | 2024 | 223 | 0.690 |
Why?
| Acclimatization | 1 | 2021 | 132 | 0.690 |
Why?
| Ascorbic Acid | 3 | 2021 | 112 | 0.670 |
Why?
| Telomere | 3 | 2010 | 204 | 0.670 |
Why?
| Cells, Cultured | 8 | 2021 | 3914 | 0.660 |
Why?
| Physical Fitness | 11 | 2005 | 179 | 0.650 |
Why?
| T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.640 |
Why?
| Blood Glucose | 7 | 2019 | 1824 | 0.630 |
Why?
| Endothelium | 3 | 2020 | 115 | 0.620 |
Why?
| Hematopoietic Stem Cells | 2 | 2011 | 346 | 0.610 |
Why?
| Metoprolol | 1 | 2017 | 37 | 0.600 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1870 | 0.590 |
Why?
| HIV | 1 | 2019 | 209 | 0.590 |
Why?
| Hyperglycemia | 2 | 2018 | 294 | 0.590 |
Why?
| Plethysmography | 5 | 2017 | 103 | 0.580 |
Why?
| HIV Infections | 4 | 2019 | 2473 | 0.570 |
Why?
| Body Mass Index | 15 | 2017 | 1971 | 0.570 |
Why?
| Receptor, Endothelin A | 2 | 2014 | 59 | 0.560 |
Why?
| Stress, Physiological | 2 | 2017 | 399 | 0.560 |
Why?
| Cytokines | 4 | 2020 | 1853 | 0.550 |
Why?
| Cellular Senescence | 1 | 2018 | 153 | 0.550 |
Why?
| Biomarkers | 11 | 2023 | 3466 | 0.550 |
Why?
| Enzyme Inhibitors | 5 | 2017 | 757 | 0.520 |
Why?
| Nitric Oxide Synthase | 4 | 2017 | 213 | 0.520 |
Why?
| Bradykinin | 7 | 2015 | 46 | 0.510 |
Why?
| Gender Identity | 2 | 2006 | 103 | 0.500 |
Why?
| Blood Pressure Determination | 2 | 2016 | 122 | 0.500 |
Why?
| Plasminogen Activator Inhibitor 1 | 6 | 2023 | 82 | 0.490 |
Why?
| Diet, High-Fat | 2 | 2018 | 225 | 0.480 |
Why?
| Blood Platelets | 1 | 2017 | 350 | 0.470 |
Why?
| Endothelial Progenitor Cells | 1 | 2014 | 19 | 0.460 |
Why?
| Analysis of Variance | 7 | 2016 | 1227 | 0.440 |
Why?
| Adiposity | 3 | 2016 | 468 | 0.440 |
Why?
| Infusions, Intra-Arterial | 5 | 2013 | 45 | 0.430 |
Why?
| Colony-Forming Units Assay | 6 | 2014 | 90 | 0.420 |
Why?
| Anti-HIV Agents | 1 | 2019 | 669 | 0.420 |
Why?
| Glucose | 1 | 2017 | 904 | 0.410 |
Why?
| Blood Vessels | 1 | 2014 | 181 | 0.410 |
Why?
| Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.410 |
Why?
| T-Lymphocytes | 2 | 2010 | 1756 | 0.410 |
Why?
| Alkalosis, Respiratory | 2 | 2023 | 2 | 0.410 |
Why?
| Coronary Disease | 3 | 2007 | 348 | 0.410 |
Why?
| Oxygen Consumption | 11 | 2024 | 573 | 0.410 |
Why?
| Young Adult | 11 | 2023 | 10470 | 0.400 |
Why?
| Glucose Intolerance | 1 | 2013 | 137 | 0.390 |
Why?
| Time Factors | 10 | 2021 | 6165 | 0.390 |
Why?
| Risk Factors | 14 | 2018 | 8697 | 0.390 |
Why?
| Muscle, Smooth, Vascular | 5 | 2010 | 420 | 0.390 |
Why?
| Fatty Acids | 1 | 2014 | 386 | 0.380 |
Why?
| Abdominal Fat | 1 | 2011 | 43 | 0.380 |
Why?
| Muscle Tonus | 2 | 2010 | 18 | 0.370 |
Why?
| Antigens, CD34 | 1 | 2011 | 90 | 0.370 |
Why?
| Body Composition | 13 | 2009 | 580 | 0.370 |
Why?
| HIV Protease Inhibitors | 1 | 2011 | 64 | 0.360 |
Why?
| HIV-1 | 2 | 2019 | 771 | 0.360 |
Why?
| Dyslipidemias | 1 | 2012 | 154 | 0.360 |
Why?
| Cholesterol, LDL | 1 | 2012 | 309 | 0.360 |
Why?
| Heart Failure | 1 | 2023 | 1963 | 0.350 |
Why?
| Chemotaxis | 1 | 2010 | 132 | 0.350 |
Why?
| Postprandial Period | 3 | 2019 | 88 | 0.350 |
Why?
| Health | 1 | 2010 | 74 | 0.340 |
Why?
| Sleep Wake Disorders | 1 | 2013 | 233 | 0.340 |
Why?
| NF-kappa B | 2 | 2023 | 639 | 0.340 |
Why?
| Feeding Behavior | 1 | 2015 | 573 | 0.340 |
Why?
| Disease | 1 | 2010 | 87 | 0.340 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 2008 | 38 | 0.340 |
Why?
| Flow Cytometry | 4 | 2019 | 1083 | 0.330 |
Why?
| Vascular Endothelial Growth Factor A | 4 | 2014 | 503 | 0.320 |
Why?
| Inflammation | 4 | 2020 | 2499 | 0.310 |
Why?
| Muscarinic Agonists | 1 | 2008 | 10 | 0.310 |
Why?
| Fasting | 4 | 2019 | 241 | 0.300 |
Why?
| Reference Values | 7 | 2016 | 744 | 0.290 |
Why?
| Reactive Oxygen Species | 2 | 2021 | 549 | 0.290 |
Why?
| omega-N-Methylarginine | 3 | 2015 | 25 | 0.290 |
Why?
| Interleukin-6 | 4 | 2021 | 677 | 0.290 |
Why?
| Endothelin Receptor Antagonists | 4 | 2011 | 58 | 0.280 |
Why?
| Adult Stem Cells | 1 | 2006 | 32 | 0.280 |
Why?
| Epigenesis, Genetic | 1 | 2010 | 526 | 0.260 |
Why?
| Double-Blind Method | 5 | 2021 | 1660 | 0.260 |
Why?
| Dinucleotide Repeats | 1 | 2005 | 4 | 0.260 |
Why?
| Walking | 5 | 2018 | 425 | 0.260 |
Why?
| Hyperthermia, Induced | 2 | 2023 | 65 | 0.260 |
Why?
| Myocardial Ischemia | 1 | 2006 | 237 | 0.250 |
Why?
| Arteries | 6 | 2018 | 250 | 0.240 |
Why?
| Estrogen Receptor alpha | 1 | 2005 | 120 | 0.240 |
Why?
| Blood Flow Velocity | 3 | 2012 | 324 | 0.240 |
Why?
| Age Factors | 8 | 2010 | 2907 | 0.230 |
Why?
| Antihypertensive Agents | 4 | 2013 | 432 | 0.230 |
Why?
| Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.230 |
Why?
| Quadriplegia | 1 | 2023 | 12 | 0.230 |
Why?
| Hypertrophy | 2 | 2023 | 110 | 0.230 |
Why?
| von Willebrand Factor | 1 | 2023 | 56 | 0.230 |
Why?
| Actinin | 1 | 2023 | 13 | 0.220 |
Why?
| Thrombophilia | 1 | 2023 | 66 | 0.220 |
Why?
| Troponin T | 1 | 2023 | 49 | 0.210 |
Why?
| Running | 5 | 2000 | 209 | 0.210 |
Why?
| Vaping | 1 | 2023 | 46 | 0.210 |
Why?
| Adipose Tissue | 5 | 2005 | 555 | 0.210 |
Why?
| Receptor, Endothelin B | 2 | 2014 | 51 | 0.200 |
Why?
| Sex Characteristics | 4 | 2017 | 641 | 0.200 |
Why?
| Electronic Nicotine Delivery Systems | 1 | 2023 | 73 | 0.200 |
Why?
| Breathing Exercises | 1 | 2021 | 19 | 0.190 |
Why?
| Inhalation | 1 | 2021 | 24 | 0.190 |
Why?
| Respiratory Muscles | 1 | 2021 | 32 | 0.190 |
Why?
| South America | 1 | 2021 | 53 | 0.190 |
Why?
| Peru | 1 | 2021 | 55 | 0.190 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2019 | 2098 | 0.190 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 28 | 0.190 |
Why?
| Lymphocyte Count | 2 | 2011 | 133 | 0.190 |
Why?
| Healthy Lifestyle | 1 | 2021 | 29 | 0.180 |
Why?
| Fibrosis | 1 | 2023 | 457 | 0.180 |
Why?
| Transcription Factor RelA | 1 | 2021 | 83 | 0.180 |
Why?
| Endothelins | 1 | 2021 | 61 | 0.180 |
Why?
| Carotid Arteries | 4 | 2003 | 183 | 0.180 |
Why?
| Drug Administration Schedule | 2 | 2016 | 724 | 0.180 |
Why?
| Transforming Growth Factor beta | 1 | 2023 | 446 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2015 | 1137 | 0.180 |
Why?
| Piperidines | 2 | 2013 | 163 | 0.180 |
Why?
| Cytochromes c | 2 | 2010 | 62 | 0.180 |
Why?
| Chemokine CXCL12 | 2 | 2010 | 74 | 0.180 |
Why?
| Interleukin-8 | 1 | 2021 | 241 | 0.170 |
Why?
| Fibrinogen | 2 | 1998 | 160 | 0.170 |
Why?
| Oligopeptides | 2 | 2013 | 248 | 0.170 |
Why?
| Fever | 2 | 2020 | 280 | 0.170 |
Why?
| Cell Proliferation | 1 | 2006 | 2194 | 0.170 |
Why?
| Colorado | 5 | 2021 | 4113 | 0.170 |
Why?
| Physical Exertion | 2 | 1998 | 206 | 0.170 |
Why?
| Insulin Glargine | 1 | 2019 | 73 | 0.170 |
Why?
| Risk Reduction Behavior | 1 | 2021 | 201 | 0.160 |
Why?
| Phenotype | 2 | 2021 | 2829 | 0.160 |
Why?
| Hemoglobins | 1 | 2021 | 312 | 0.160 |
Why?
| E-Selectin | 1 | 2018 | 54 | 0.160 |
Why?
| HIV Antibodies | 1 | 2019 | 49 | 0.160 |
Why?
| Myocytes, Cardiac | 1 | 2023 | 457 | 0.160 |
Why?
| Telomerase | 2 | 2011 | 206 | 0.160 |
Why?
| Infusions, Intravenous | 2 | 2011 | 374 | 0.160 |
Why?
| Heat-Shock Response | 1 | 2018 | 46 | 0.160 |
Why?
| Brachial Artery | 3 | 2017 | 173 | 0.160 |
Why?
| Follow-Up Studies | 3 | 2017 | 4440 | 0.160 |
Why?
| Treatment Outcome | 5 | 2021 | 9159 | 0.160 |
Why?
| Pilot Projects | 1 | 2023 | 1377 | 0.160 |
Why?
| Myocardial Infarction | 1 | 2005 | 931 | 0.150 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 9 | 0.150 |
Why?
| Antioxidants | 1 | 2021 | 533 | 0.150 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 36 | 0.150 |
Why?
| Exercise Therapy | 3 | 2017 | 351 | 0.150 |
Why?
| Lipids | 3 | 2009 | 588 | 0.150 |
Why?
| Dietary Carbohydrates | 1 | 2018 | 135 | 0.150 |
Why?
| Heart | 1 | 2021 | 608 | 0.140 |
Why?
| Prognosis | 3 | 2018 | 3339 | 0.140 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 155 | 0.140 |
Why?
| Anthropometry | 2 | 2011 | 181 | 0.130 |
Why?
| Infusions, Intraosseous | 1 | 2016 | 20 | 0.130 |
Why?
| Triglycerides | 3 | 2005 | 473 | 0.130 |
Why?
| Phosphorylation | 1 | 2020 | 1571 | 0.130 |
Why?
| Enzyme Activation | 1 | 2017 | 793 | 0.130 |
Why?
| Hot Temperature | 1 | 2017 | 303 | 0.130 |
Why?
| Substance P | 2 | 2008 | 44 | 0.130 |
Why?
| Isoproterenol | 2 | 2008 | 110 | 0.120 |
Why?
| Blood Circulation | 1 | 2015 | 35 | 0.120 |
Why?
| Down-Regulation | 1 | 2017 | 601 | 0.120 |
Why?
| Cross-Over Studies | 4 | 2017 | 434 | 0.120 |
Why?
| Interleukin-18 | 2 | 2006 | 222 | 0.120 |
Why?
| Peptides | 1 | 2019 | 864 | 0.120 |
Why?
| Signal Transduction | 3 | 2014 | 4541 | 0.120 |
Why?
| Hydrocortisone | 1 | 2015 | 273 | 0.110 |
Why?
| Interleukin-10 | 1 | 2015 | 299 | 0.110 |
Why?
| Regression Analysis | 4 | 2011 | 959 | 0.100 |
Why?
| Hypoglycemic Agents | 1 | 2019 | 1008 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2015 | 371 | 0.100 |
Why?
| Cholinergic Agonists | 1 | 2011 | 7 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 204 | 0.100 |
Why?
| Blood Volume | 4 | 1999 | 56 | 0.100 |
Why?
| Obesity, Abdominal | 1 | 2011 | 38 | 0.090 |
Why?
| Prevalence | 3 | 2014 | 2264 | 0.090 |
Why?
| Plaque, Atherosclerotic | 1 | 2011 | 43 | 0.090 |
Why?
| Waist Circumference | 1 | 2011 | 122 | 0.090 |
Why?
| Vital Capacity | 2 | 2002 | 277 | 0.090 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2011 | 174 | 0.090 |
Why?
| Femoral Artery | 2 | 2002 | 167 | 0.090 |
Why?
| Cholesterol | 2 | 2005 | 369 | 0.090 |
Why?
| Plant Lectins | 1 | 2010 | 8 | 0.090 |
Why?
| Staurosporine | 1 | 2010 | 21 | 0.090 |
Why?
| Estrogens | 2 | 2003 | 315 | 0.090 |
Why?
| Cerebrovascular Circulation | 2 | 2023 | 202 | 0.090 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 70 | 0.090 |
Why?
| Bone Diseases, Metabolic | 1 | 2010 | 53 | 0.090 |
Why?
| CD3 Complex | 1 | 2009 | 92 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 193 | 0.080 |
Why?
| Cell Separation | 1 | 2010 | 293 | 0.080 |
Why?
| Leg | 2 | 2001 | 227 | 0.080 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 332 | 0.080 |
Why?
| Baroreflex | 2 | 2000 | 53 | 0.080 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 400 | 0.080 |
Why?
| Norepinephrine | 1 | 2009 | 207 | 0.080 |
Why?
| Up-Regulation | 1 | 2012 | 820 | 0.080 |
Why?
| Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| Aspartic Acid Endopeptidases | 1 | 2008 | 21 | 0.080 |
Why?
| Metalloendopeptidases | 1 | 2008 | 55 | 0.080 |
Why?
| Methacholine Chloride | 1 | 2008 | 47 | 0.080 |
Why?
| Cell Count | 1 | 2008 | 305 | 0.080 |
Why?
| Calcium Channel Blockers | 1 | 2008 | 115 | 0.080 |
Why?
| Life Style | 4 | 2003 | 429 | 0.070 |
Why?
| Hemiplegia | 2 | 1997 | 19 | 0.070 |
Why?
| Risk Assessment | 1 | 2016 | 2987 | 0.070 |
Why?
| Arm | 1 | 2007 | 105 | 0.070 |
Why?
| Coronary Circulation | 1 | 2007 | 128 | 0.070 |
Why?
| Muscle, Skeletal | 3 | 2002 | 1447 | 0.070 |
Why?
| Probability | 1 | 2007 | 294 | 0.070 |
Why?
| Lipoproteins, LDL | 1 | 2006 | 129 | 0.070 |
Why?
| Aged, 80 and over | 5 | 2003 | 6417 | 0.070 |
Why?
| DNA Methylation | 1 | 2010 | 498 | 0.070 |
Why?
| Microscopy, Phase-Contrast | 1 | 2005 | 18 | 0.070 |
Why?
| Thymidine | 1 | 2005 | 58 | 0.060 |
Why?
| Weight Loss | 1 | 2010 | 633 | 0.060 |
Why?
| Bone Marrow Cells | 1 | 2005 | 268 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 373 | 0.060 |
Why?
| Thrombosis | 1 | 2007 | 302 | 0.060 |
Why?
| Anaerobic Threshold | 2 | 2005 | 19 | 0.060 |
Why?
| France | 1 | 2024 | 34 | 0.060 |
Why?
| Hypocapnia | 1 | 2023 | 5 | 0.060 |
Why?
| Hyperventilation | 1 | 2023 | 8 | 0.060 |
Why?
| Adenine | 1 | 2005 | 221 | 0.060 |
Why?
| Oxidation-Reduction | 1 | 2006 | 924 | 0.060 |
Why?
| Body Weight | 2 | 2005 | 867 | 0.050 |
Why?
| Bicycling | 1 | 2024 | 74 | 0.050 |
Why?
| Hypertriglyceridemia | 1 | 2003 | 34 | 0.050 |
Why?
| Fenofibrate | 1 | 2003 | 24 | 0.050 |
Why?
| Muscarinic Antagonists | 1 | 2003 | 27 | 0.050 |
Why?
| Physical Education and Training | 1 | 2003 | 60 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 1718 | 0.050 |
Why?
| Exercise Test | 3 | 2005 | 539 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2005 | 621 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 211 | 0.050 |
Why?
| Carotid Artery Diseases | 1 | 2002 | 58 | 0.050 |
Why?
| Progesterone | 1 | 2003 | 232 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 129 | 0.050 |
Why?
| Tunica Intima | 4 | 2002 | 78 | 0.050 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2000 | 40 | 0.050 |
Why?
| Knee | 1 | 2000 | 50 | 0.050 |
Why?
| Heart Rate | 3 | 1998 | 701 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2005 | 1805 | 0.040 |
Why?
| Compliance | 3 | 2008 | 44 | 0.040 |
Why?
| Oxygen | 1 | 2024 | 837 | 0.040 |
Why?
| Social Class | 1 | 2001 | 210 | 0.040 |
Why?
| Energy Intake | 2 | 1998 | 414 | 0.040 |
Why?
| Hemorheology | 1 | 2018 | 20 | 0.040 |
Why?
| Drug Combinations | 1 | 2019 | 289 | 0.040 |
Why?
| Body Constitution | 1 | 1998 | 47 | 0.040 |
Why?
| Diet, Fat-Restricted | 1 | 2018 | 73 | 0.040 |
Why?
| Microvessels | 1 | 2018 | 68 | 0.040 |
Why?
| Hemostasis | 1 | 1998 | 67 | 0.040 |
Why?
| Ultrasonography | 4 | 2002 | 641 | 0.040 |
Why?
| Premenopause | 4 | 1999 | 103 | 0.040 |
Why?
| United States | 1 | 2014 | 12295 | 0.040 |
Why?
| Cervical Vertebrae | 1 | 2018 | 105 | 0.040 |
Why?
| Plasminogen Activators | 1 | 1997 | 7 | 0.040 |
Why?
| Gait | 2 | 1997 | 249 | 0.040 |
Why?
| Cohort Studies | 1 | 2007 | 4944 | 0.040 |
Why?
| Vascular Resistance | 1 | 1998 | 338 | 0.040 |
Why?
| Movement Disorders | 1 | 1997 | 46 | 0.030 |
Why?
| Neoplasms | 1 | 2010 | 2118 | 0.030 |
Why?
| Cerebrovascular Disorders | 1 | 1997 | 82 | 0.030 |
Why?
| Chromium | 1 | 1996 | 12 | 0.030 |
Why?
| Weight Lifting | 1 | 1996 | 29 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2018 | 501 | 0.030 |
Why?
| Insulin | 1 | 2005 | 2082 | 0.030 |
Why?
| Hypoxia | 1 | 2021 | 937 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2017 | 1127 | 0.030 |
Why?
| Antigens | 1 | 1996 | 323 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1216 | 0.030 |
Why?
| Melatonin | 1 | 2015 | 106 | 0.030 |
Why?
| Menopause | 1 | 1997 | 262 | 0.030 |
Why?
| Swimming | 3 | 1999 | 45 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 1997 | 285 | 0.030 |
Why?
| Brain Ischemia | 1 | 1997 | 298 | 0.030 |
Why?
| Tunica Media | 2 | 2001 | 35 | 0.020 |
Why?
| Sex Factors | 1 | 1996 | 1736 | 0.020 |
Why?
| Brain | 1 | 2020 | 2370 | 0.020 |
Why?
| Cardiac Output | 2 | 1998 | 143 | 0.020 |
Why?
| Prospective Studies | 4 | 2001 | 6264 | 0.020 |
Why?
| Bone Density | 1 | 2010 | 432 | 0.020 |
Why?
| Stroke Volume | 2 | 1998 | 509 | 0.020 |
Why?
| Adolescent | 5 | 2002 | 17889 | 0.020 |
Why?
| Hemostatics | 1 | 2005 | 48 | 0.020 |
Why?
| Hypolipidemic Agents | 1 | 2003 | 87 | 0.010 |
Why?
| Fatty Acids, Nonesterified | 1 | 2003 | 151 | 0.010 |
Why?
| Lipoproteins | 1 | 2003 | 162 | 0.010 |
Why?
| Absorptiometry, Photon | 1 | 2002 | 221 | 0.010 |
Why?
| Blood Viscosity | 1 | 2001 | 17 | 0.010 |
Why?
| Habits | 1 | 2001 | 37 | 0.010 |
Why?
| Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| Thigh | 1 | 2000 | 53 | 0.010 |
Why?
| Mexico | 1 | 2001 | 163 | 0.010 |
Why?
| Thinness | 1 | 2000 | 87 | 0.010 |
Why?
| Elasticity | 1 | 2000 | 194 | 0.010 |
Why?
| Erythrocyte Volume | 1 | 1999 | 4 | 0.010 |
Why?
| Femur | 1 | 2001 | 194 | 0.010 |
Why?
| Plasma Volume | 1 | 1999 | 13 | 0.010 |
Why?
| Stress, Mechanical | 1 | 2001 | 440 | 0.010 |
Why?
| Supine Position | 1 | 1998 | 34 | 0.010 |
Why?
| Posture | 1 | 1999 | 150 | 0.010 |
Why?
| Signal Processing, Computer-Assisted | 1 | 1998 | 137 | 0.010 |
Why?
| Hematocrit | 1 | 1997 | 86 | 0.010 |
Why?
| Rest | 1 | 1997 | 100 | 0.010 |
Why?
| Electric Conductivity | 1 | 1997 | 91 | 0.010 |
Why?
| Ventricular Fibrillation | 1 | 1997 | 51 | 0.010 |
Why?
| Electrodes, Implanted | 1 | 1997 | 92 | 0.010 |
Why?
| Hyperlipidemias | 1 | 1997 | 124 | 0.010 |
Why?
| Electrocardiography | 1 | 1998 | 560 | 0.010 |
Why?
| Diabetes Complications | 1 | 1997 | 212 | 0.010 |
Why?
| Tachycardia, Ventricular | 1 | 1997 | 152 | 0.010 |
Why?
| Equipment Design | 1 | 1997 | 517 | 0.010 |
Why?
| Multivariate Analysis | 1 | 1998 | 1440 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1078 | 0.010 |
Why?
| Kinetics | 1 | 1997 | 1569 | 0.010 |
Why?
| Animals | 2 | 2008 | 32102 | 0.010 |
Why?
| Stroke | 1 | 2002 | 1016 | 0.010 |
Why?
| Heart Arrest | 1 | 1997 | 289 | 0.010 |
Why?
| Survival Rate | 1 | 1997 | 1650 | 0.010 |
Why?
| Length of Stay | 1 | 1997 | 958 | 0.010 |
Why?
| Energy Metabolism | 1 | 1997 | 715 | 0.010 |
Why?
| Smoking | 1 | 1997 | 1457 | 0.010 |
Why?
| Retrospective Studies | 1 | 2003 | 12608 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|